Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
March 09, 2017 16:01 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, March 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today reported financial results for the fourth quarter and full year ended December 31, 2016.“In 2016, we...
Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
February 27, 2017 09:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cowen and...
Cascadian Therapeutics Prices $82.5 Million Concurrent Offerings of Common Stock and Preferred Stock
January 24, 2017 08:50 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the pricing of the previously announced concurrent...
Cascadian Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
January 23, 2017 16:01 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell shares of its...
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress
January 05, 2017 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for its...
Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and Quality
January 04, 2017 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the appointment of Marc L. Lesnick, Ph.D., as...
Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration
December 07, 2016 07:00 ET
|
Cascadian Therapeutics, Inc.
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response (MDR) at 10 Months in Third-line Setting for...
Cascadian Therapeutics Strengthens Management Team with Key Hires, Monique M. Greer and Marc C. Chamberlain, M.D.
November 28, 2016 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the Company strengthened its leadership team...
Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split
November 23, 2016 16:05 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that at a special meeting held on November 18,...
Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the 2016 San Antonio Breast Cancer Symposium
November 15, 2016 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that two abstracts on the Company’s lead product...